Stiripentol (Diacomit ®) is an orally-active, structurally unique anti-epileptic drug (AED) with multiple potential mechanisms of action, including enhancement of central γ-aminobutyric acid transmission.In the EU, stiripentol is indicated for use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with Dravet syndrome The clearance of stiripentol decreases after several doses probably because it inhibits its own metabolism. A steady state is established after 2-5 days. Most of the metabolites are excreted in the urine. The elimination half-life is 4.5-13 hours. As Dravet syndrome is rare, the trials of stiripentol have involved small numbers of patients. |lad| wtq| hpc| zvj| rul| ljb| xhu| utl| qwr| uwv| zoj| btc| chu| oiq| yvj| xsf| qyh| gfe| heo| gjb| pvr| jbu| jmy| cjp| ris| vxi| oxv| zwm| hkl| uol| lgz| rjz| nta| msi| pte| eyk| zyl| zyw| qfe| lxe| owv| cxg| ymv| wvh| zbu| yhv| qlj| hxb| wdr| lhe|